Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study showed ...
apartment of generous dimensions in a quality complex benefits from a seamless floor plan. Moments away from the Train Station, Westfields, Cafes, Restaurants and exclusive schools both private and ...
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback